Cargando…
Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction
Currently the world faces epidemic of several closely related conditions: obesity, metabolic syndrome and type 2 diabetes (T2DM). The lipid profile of these patients and those with metabolic syndrome is characterized by the concurrent presence of qualitative as well as quantitative lipoprotein abnor...
Autores principales: | Tenenbaum, Alexander, Fisman, Enrique Z |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489608/ https://www.ncbi.nlm.nih.gov/pubmed/23057687 http://dx.doi.org/10.1186/1475-2840-11-125 |
Ejemplares similares
-
Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
por: Tenenbaum, Alexander, et al.
Publicado: (2006) -
Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?
por: Tenenbaum, Alexander, et al.
Publicado: (2004) -
Anti-atherogenic effects of fibrates in type 2 diabetes
por: Barter, Philip
Publicado: (2001) -
Atherogenic dyslipidemia
por: Manjunath, C. N., et al.
Publicado: (2013) -
Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study
por: Chan, Sammy Y, et al.
Publicado: (2008)